Patents by Inventor Mark Brian Pepys

Mark Brian Pepys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antigen binding proteins
    Patent number: 10221234
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 5, 2019
    Assignee: Glaxo Group Limited
    Inventors: Tejinder Kaur Bhinder, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Antigen binding proteins
    Patent number: 9434716
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: September 6, 2016
    Assignee: Glaxo Group Limited
    Inventors: Tejinder Kaur Bhinder, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Variant Beta2-microglobulin, characterization of the same and applications thereof
    Publication number: 20130331327
    Abstract: This invention relates to the specific Asp76Asn (D76N) variant ?2-microglobulin (?2M) protein, nucleic acids encoding the same, their characterization and applications in studying amyloid fibrillogenesis, including diagnostic and therapeutic applications.
    Type: Application
    Filed: June 8, 2012
    Publication date: December 12, 2013
    Inventors: Vittorio Bellotti, Sophie Valleix, Mark Brian Pepys, Madeleine M. Riès-Kautt
  • ANTIGEN BINDING PROTEINS
    Publication number: 20120225055
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Application
    Filed: March 1, 2011
    Publication date: September 6, 2012
    Inventors: Tejinder Kaur BHINDER, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Compound and use thereof in the treatment of amyloidosis
    Patent number: 8236984
    Abstract: The present invention relates to compounds of formula (I) for stabilizing the tetrameric form of transthyretin, compounds for use in the treatment or prevention of amyloidosis, and agents and medicaments comprising such compounds. wherein X, Y, R1, R2, R3, R4, m, n, p, q, and the linker are as defined herein.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: August 7, 2012
    Assignee: Pentraxin Therapeutics Ltd.
    Inventors: Mark Brian Pepys, Steven Victor Ley, Angus John Morrison, Vittorio Bellotti, Simon Kolstoe, Martin Smith